Back to Search
Start Over
Performance of Plasma HSP90α, Serum EBV VCA IgA Antibody and Plasma EBV DNA for the Diagnosis and Prognosis Prediction of Nasopharyngeal Carcinoma
- Source :
- Cancer Management and Research
- Publication Year :
- 2021
- Publisher :
- Informa UK Limited, 2021.
-
Abstract
- Qian Ye, Junying Guo, Yansong Chen, Zhaolei Cui, Yan Chen Department of Laboratory Medicine, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou City, Fujian Province, 350014, Peopleâs Republic of ChinaCorrespondence: Zhaolei Cui; Yan ChenDepartment of Laboratory Medicine, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, No. 420 Fuma Road, Jinâan District, Fuzhou City, Fujian Province, 350014, Peopleâs Republic of ChinaEmail cuileidizi@163.com; chenyan220422@fjmu.edu.cnObjective: The aim of this study was to evaluate the effectiveness of EpsteinâBarr virus (EBV) VCA-IgA antibody, EBV DNA and HSP90α alone or in combinations for the diagnosis and prognostic prediction of nasopharyngeal carcinoma (NPC).Methods: A total of 113 treatment-naïve patients with NPC and 40 healthy controls were enrolled. Plasma HSP90α and serum EBV VCA IgA antibody were detected using ELISA, and plasma EBV DNA was quantified using qPCR assay. The effectiveness of plasma HSP90α level, serum EBV VCA IgA antibody and plasma EBV DNA was examined in the diagnosis and prognosis prediction of NPC.Results: Higher plasma HSP90α, serum EBV VCA IgA antibody and plasma viral load of EBV DNA were detected in NPC patients than in healthy controls (P < 0.001). The plasma HSP90α levels, serum EBV VCA IgA antibody titers and plasma viral load of EBV DNA were significantly greater in NPC patients with stages III and IV than in those with stages I and II (P < 0.001), and significantly lower plasma HSP90α levels, serum EBV VCA IgA antibody titers and plasma viral load of EBV DNA were found in the good prognosis group than in the poor prognosis group post-treatment (P < 0.05). The area under representative operating curves (AUCs) of plasma HSP90α, serum EBV VCA IgA antibody and plasma EBV DNA alone and in combination were 0.884, 0.841, 0.934 and 0.954 for the diagnosis of NPC, respectively. Univariate and multivariate Cox proportional hazards regression analyses identified HSP90α as an independent prognostic factor for NPC.Conclusion: The combination of plasma HSP90α, serum EBV VCA IgA antibody and plasma EBV DNA shows high diagnostic performance for NPC, and plasma HSP90α may be a potential marker for diagnosis and prognosis prediction of NPC.Keywords: nasopharyngeal carcinoma, EBV VCA-IgA antibody, EBV DNA, HSP90α, diagnostic performance, prognosis prediction
- Subjects :
- Prognosis prediction
EBV DNA
Virus
Plasma viral load
diagnostic performance
HSP90α
hemic and lymphatic diseases
Cox proportional hazards regression
otorhinolaryngologic diseases
medicine
EBV VCA-IgA antibody
IgA antibody
Original Research
biology
business.industry
nasopharyngeal carcinoma
medicine.disease
stomatognathic diseases
Titer
Oncology
Nasopharyngeal carcinoma
Cancer Management and Research
Immunology
biology.protein
prognosis prediction
Antibody
business
Subjects
Details
- ISSN :
- 11791322
- Volume :
- 13
- Database :
- OpenAIRE
- Journal :
- Cancer Management and Research
- Accession number :
- edsair.doi.dedup.....6a138456ad5da10490e3344a71e24fea
- Full Text :
- https://doi.org/10.2147/cmar.s320541